Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 16/20 | 0.48 |
| ▸ | ITGA2B | P08514 | 16/20 | 0.48 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.43 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.43 |
| ▸ | ITGAV | P06756 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | DHODH | Q02127 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12103493 | 0.88 | ITGB3 (0.53) | ITGB3ITGA2BITGAVCHRM2SLC6A4 | |
| SCHEMBL12160436 | 0.87 | ITGB3 (0.47) | ITGB3ITGA2BITGAVCHRM2SLC6A4 | |
| SCHEMBL2568966 | 0.87 | ITGB3 (0.47) | ITGB3ITGA2BCHEK1CHEK2 | |
| Hydrochloric Acid SCHEMBL1296299 | 0.87 | ITGB3 (0.52) | ITGB3ITGA2BITGAVCHRM2SLC6A4 | |
| SCHEMBL12106765 | 0.87 | ITGB3 (0.49) | ITGB3ITGA2BCHEK2ITGAVCHRM2 | |
| SCHEMBL25547191 | 0.85 | ITGB3 (0.53) | ITGB3ITGA2BITGAVCHRM2SLC6A4 | |
| SCHEMBL22310562 | 0.84 | ITGB3 (0.52) | ITGB3ITGA2BITGAVCHRM2SLC6A4 | |
| SCHEMBL12106843 | 0.84 | ITGB3 (0.44) | ITGB3ITGA2B | |
| SCHEMBL1839393 | 0.83 | GPR119 (0.46) | — | |
| Hydrochloric Acid SCHEMBL1295876 | 0.83 | ITGB3 (0.43) | ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2321308-B9 | PIPERIDINE GPCR AGONISTS | PROSIDION LTD (GB) | 2012-08-08 | — | — | EP | disclosed |
| EP-2321308-B9 | PIPERIDINE GPCR AGONISTS | PROSIDION LTD (GB) | 2012-08-08 | — | — | EP | disclosed |
| EP-2321308-B1 | PIPERIDINE GPCR AGONISTS | PROSIDION LTD (GB) | 2012-05-09 | — | — | EP | disclosed |
| EP-2321308-B1 | PIPERIDINE GPCR AGONISTS | PROSIDION LTD (GB) | 2012-05-09 | — | — | EP | disclosed |
| US-20110269734-A1 | PIPERIDINYL GPCR AGONISTS | PROSIDION LIMITED (GB) | 2011-11-03 | — | — | US | disclosed |
| WO-2011128394-A1 | 3-SUBSTITUTED 5-(PYRROLIDINE-1-CARBONYL) PYRROLIDINE AND ITS DERIVATIVES FOR USE IN THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2011-10-20 | — | — | WO | disclosed |
| WO-2011128394-A1 | 3-SUBSTITUTED 5-(PYRROLIDINE-1-CARBONYL) PYRROLIDINE AND ITS DERIVATIVES FOR USE IN THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2011-10-20 | — | — | WO | disclosed |
| US-20110230507-A1 | Piperidine GPCR Agonists | PROSIDION LIMITED (GB) | 2011-09-22 | — | — | US | disclosed |
| US-20110178054-A1 | Heterocyclic GPCR Agonists | PROSIDION LIMITED (GB) | 2011-07-21 | — | — | US | disclosed |
| CN-102089301-A | Piperidine gpcr agonists | PROSIDION LTD | 2011-06-08 | — | — | CN | disclosed |
| CN-102083813-A | Piperidinyl gpcr agonists | PROSIDION LTD | 2011-06-01 | — | — | CN | disclosed |
| EP-2321308-A1 | PIPERIDINE GPCR AGONISTS | Prosidion Limited (GB) | 2011-05-18 | — | — | EP | disclosed |
| EP-2321297-A1 | PIPERIDINYL GPCR AGONISTS | Prosidion Limited (GB) | 2011-05-18 | — | — | EP | disclosed |
| WO-2010004343-A1 | PIPERIDINYL GPCR AGONISTS | PROSIDION LIMITED (GB) | 2010-01-14 | — | — | WO | disclosed |
| WO-2010004343-A1 | PIPERIDINYL GPCR AGONISTS | PROSIDION LIMITED (GB) | 2010-01-14 | — | — | WO | disclosed |
| WO-2010004344-A1 | PIPERIDINE GPCR AGONISTS | PROSIDION LIMITED (GB) | 2010-01-14 | — | — | WO | disclosed |
| WO-2010004344-A1 | PIPERIDINE GPCR AGONISTS | PROSIDION LIMITED (GB) | 2010-01-14 | — | — | WO | disclosed |
| WO-2010004348-A1 | HETEROCYCLIC GPCR AGONISTS | PROSIDION LIMITED (GB) | 2010-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178054-A1 | Heterocyclic GPCR Agonists | GPR119, GCGR, GPR27 | ITGB3 3139/4885ITGA2B 2241/4885CHEK1 4112/4885 |
| US-20110269734-A1 | PIPERIDINYL GPCR AGONISTS | GPR119, GPR27, GLP1R | ITGB3 3442/4885ITGA2B 3353/4885CHEK1 4157/4885 |
| US-20110230507-A1 | Piperidine GPCR Agonists | GPR119, GPR27, GLP1R | ITGB3 3495/4885ITGA2B 3176/4885CHEK1 3969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.